IFM Investors Pty Ltd lifted its holdings in Pfizer Inc. (NYSE:PFE) by 13.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 462,232 shares of the biopharmaceutical company’s stock after purchasing an additional 54,711 shares during the period. Pfizer accounts for about 0.7% of IFM Investors Pty Ltd’s investment portfolio, making the stock its 26th biggest holding. IFM Investors Pty Ltd’s holdings in Pfizer were worth $16,964,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Corbett Road Capital Management LLC acquired a new stake in shares of Pfizer in the 2nd quarter valued at $25,000. Reitz Capital Advisors LLC acquired a new position in Pfizer during the 2nd quarter worth $29,000. Disciplined Investments LLC lifted its position in Pfizer by 43.3% during the 1st quarter. Disciplined Investments LLC now owns 1,148 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 347 shares during the last quarter. Rocky Mountain Advisers LLC lifted its position in Pfizer by 847.5% during the 2nd quarter. Rocky Mountain Advisers LLC now owns 1,118 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 1,000 shares during the last quarter. Finally, JJJ Advisors Inc. acquired a new position in Pfizer during the 2nd quarter worth $44,000. 69.08% of the stock is owned by institutional investors and hedge funds.

NYSE PFE traded up $1.40 on Friday, reaching $37.95. The company’s stock had a trading volume of 40,790,772 shares, compared to its average volume of 28,495,957. The firm has a market cap of $210.88 billion, a PE ratio of 15.06, a price-to-earnings-growth ratio of 2.91 and a beta of 0.67. The business has a 50-day moving average price of $36.59 and a 200 day moving average price of $36.32. Pfizer Inc. has a 52 week low of $27.88 and a 52 week high of $40.97. The company has a current ratio of 1.42, a quick ratio of 1.16 and a debt-to-equity ratio of 0.78.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, July 28th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.64 by $0.14. The business had revenue of $11.80 billion for the quarter, compared to analysts’ expectations of $11.55 billion. Pfizer had a net margin of 28.80% and a return on equity of 25.11%. The firm’s revenue for the quarter was down 11.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.80 earnings per share. Analysts anticipate that Pfizer Inc. will post 2.89 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 1st. Investors of record on Friday, November 6th will be paid a $0.38 dividend. The ex-dividend date is Thursday, November 5th. This represents a $1.52 dividend on an annualized basis and a yield of 4.01%. Pfizer’s payout ratio is currently 51.53%.

A number of research firms have weighed in on PFE. SVB Leerink boosted their target price on shares of Pfizer from $39.00 to $42.00 and gave the stock a “market perform” rating in a research report on Wednesday, July 29th. UBS Group boosted their target price on shares of Pfizer from $37.00 to $39.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 29th. Piper Sandler boosted their target price on shares of Pfizer from $18.50 to $24.00 in a research report on Friday, June 26th. Atlantic Securities lowered shares of Pfizer from an “overweight” rating to a “neutral” rating and cut their target price for the stock from $44.00 to $39.00 in a research report on Monday, October 12th. Finally, Berenberg Bank assumed coverage on shares of Pfizer in a research report on Tuesday, September 29th. They set a “hold” rating and a $38.00 target price for the company. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and four have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $39.64.

In other Pfizer news, Director Ronald E. Blaylock bought 13,000 shares of the stock in a transaction that occurred on Thursday, August 6th. The shares were acquired at an average price of $38.55 per share, with a total value of $501,150.00. Following the completion of the purchase, the director now directly owns 4,000 shares in the company, valued at approximately $154,200. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.08% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Recommended Story: Learning About the VIX – Volatility Index

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.